Although chemotherapy is currently established as a standard treatment in recurrent or metastatic gastric cancer, the role of palliative surgical resection is still controversial. We investigated the survival benefit of surgical resection in patients (pts) with recurrent or metastatic gastric cancer who received systemic chemotherapy.
A retrospective review was conducted on 696 pts who received palliative chemotherapy for recurrent (n = 307) or primary metastatic (n = 389) gastric cancer. Overall survival (OS) of pts who underwent surgical resection followed by chemotherapy was compared to that of pts who received chemotherapy alone.
Among 138 pts (primary metastatic: 96, recurrent: 42) with surgical resection, gastrectomy, metastasectomy, and gastrectomy with metastasectomy were performed in 83 (primary metastatic: 81), 42, and 13 pts, respectively. Higher surgical resection rate was observed in pts with young age (
The present study suggests that judicious use of surgical resection before chemotherapy in recurrent or metastatic gastric cancer pts may result in favorable outcome, although large scale phase III trials are essential to establish this treatment approach as a standard practice.
Clinical trial identification
Legal entity responsible for the study
Ajou University School of Medicine
Samyang Biopharmaceuticals Corporation, Korea
All authors have declared no conflicts of interest.